NVAX - Sector: Healthcare --- Industry: Biotechnology & Drugs

[vic666]

well...my just sold my shares at $6.27 (bought them at $5.87 last week) ...

earnings jitters make me nervous....lost bad holding thru' earnings...

anyways, afterbreaking thru' friday's high of $6.24 next resistance is recent high of $6.48...

good luck to those long. 

[Terliso]

Thanks for the reminder Tokyopua, I always put tight stop especially when I short stocks..
I don't have position yet in NVAX i'm still timing my entry point it might go up a little bit more say 5.40 to 5.60 just below 50 SMA...from there, i'll take that opportunity to short it while NVAX still bearish...

Well.. it is a good short ....well, to be honest I almost got panic when NVAX hits above 6
I'm still holding my short, NVAX may found support @ 200EMA just above 4 (I'll cover there)

Weekly chart is Bearsih...

[Terliso]

My NVAX (short) is doing good
same plan will cover just above $4

[la-onda]

NVAX: Q1 EPS (11c) vs (22c) Beats (14c) Est
Monday , May 15, 2006 07:48 ET

QUARTER RESULTS
Novavax, Inc. (NVAX) reported Q1 results ended March 2006. Q1 Revenues were $1.30M; +35.42% vs yr-ago; BEATING revenue consensus by +58.54%. Q1 EPS was (11c); +50.00% vs yr-ago; BEATING earnings consensus by +21.43%.

[REALDEALS21]

Good CC call for NVAX with losses being smaller !

Novavax Q1 loss narrows
Mon May 15, 2006 7:21 AM ET
May 15 (Reuters) -
                            NOVAVAX INC. (NVAX.O: Quote, Profile, Research)
                        Latest   Yr ago qtr
Loss (diluted, $/shr)      0.11       0.22
Net loss ($ million)        5.5        8.9
Total revenue
($ thousands)           1,303       962
--The specialty biotechnology company said in the latest
first quarter it had stock-based compensation expense.
  --For the latest first quarter, two analysts on average
had expected the company to post a loss of 14 cents a share,
before exceptional items, on revenue of $0.8 million, according
to Reuters Estimates.

[Terliso]

Nice!!!

almost time for covering

[Terliso]

I just Covered now @ 4.17.... 24.86% profit
Yahooooooooooooooooooooooooooo.................

[kslifka]

Move today may be due to speculation of Human to Human bird flu cases in Indonesia.

http://www.bloomberg.com/apps/news?pid=10000080&sid=aWESsJvt6CFE&refer=asia

[D&Data]

Novax up 20% like GNBT...HEB...

Here's the link :

http://biz.yahoo.com/ap/060523/aftermarket_movers.html?.v=1

[setravis]

• Novavax newest member of NASDAQ Biotech Index

MALVERN, Pa., May 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Novavax, Inc. (NVAX, Trade), said today that it has been added to the NASDAQ Biotechnology Index as of May 19, 2006. Novavax has traded on the exchange since July 10, 2001.

"This is an important recognition of Novavax as a seasoned public company," said Novavax President and Chief Executive Officer, Dr. Rahul Singhvi. "We continue to move forward in our goal of developing unique vaccines that protect against contagious diseases, such as the H5N1 pandemic influenza, that endanger public health around the world."

Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet certain minimum requirements, among them having a market capitalization of $200 million and average daily trading volume of 100,000 shares. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. Full eligibility criteria can be found at http://www.nasdaq.com.

About Novavax, Inc.

Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.

Forward-Looking Statements

Statements made in this press release that state Novavax's or management's intentions, hopes, beliefs, expectations, or predictions of the future are forward-looking statements. Forward-looking statements include but are not limited to statements regarding usage of cash, product sales, future product development and related clinical trials and future research and development, including FDA approval. Novavax's actual results could differ materially from those expressed in such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: general economic and business conditions; ability to enter into future collaborations with industry partners, competition; unexpected changes in technologies and technological advances; ability to obtain rights to technology; ability to obtain and enforce patents; ability to commercialize and manufacture products; ability to establish and maintain commercial-scale manufacturing capabilities; results of clinical studies; progress of research and development activities; business abilities and judgment of personnel; availability of qualified personnel; changes in, or failure to comply with, governmental regulations; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity financing or otherwise; and other factors referenced herein. Additional information is contained in Novavax's annual report on Form 10K for the year ended December 31, 2005 and quarterly report on Form 10Q for the quarter ended March 31, 2006 incorporated herein by reference. Statements made herein should be read in conjunction with Novavax's annual and quarterly reports filed with the SEC. Copies of these filings may be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the SEC at http://www.sec.gov.

SOURCE Novavax, Inc.


Cheryl Marley of Novavax, Inc., +1-484-913-1202, or [email protected] 

http://www.prnewswire.com 

Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Saturday, 05-20-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 04-06-2006 for NVAX @ $6.03. (C) 2006 Comtex News Network, Inc. All rights reserved.

[Terliso]

Novax up 20% like GNBT...HEB...

Here's the link :

http://biz.yahoo.com/ap/060523/aftermarket_movers.html?.v=1

Those 3 went up but still bearish

[Melf Elf]

I just Covered now @ 4.17.... 24.86% profit
Yahooooooooooooooooooooooooooo.................

Alister,

NICE trade...Applause!  Good timing on that exit, too! 

[Terliso]

NICE trade...Applause!  Good timing on that exit, too! 

Thanks Melf.... Timing is everything & a little bit of luck

[digdug42]

NVAX just had about 1 million shares traded in the last 10 minutes and shot up a lot.  Something is going on here behind the scenes.  Anyone see any news out? Jumped about $0.25 in this time all of a sudden.

[lovethebag]

with all the news about human 2 human bird flu and with the summer to come soon, with more bird flues to be expected on other countries i would not short this one now.